MKS Instruments vs State Street SPDR S&P Biotech ETF — how do they compare? MKS Instruments trades at $265.61 (market cap $17.61B), while State Street SPDR S&P Biotech ETF trades at $153.72 (market cap $10.11B). The key difference: MKS Instruments is the larger of the two by market cap, and MKS Instruments pays a 0.38% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold MKS Instruments for 7 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MKSI | XBI | |
|---|---|---|
Market Cap | $17.61B | $10.11B |
Volume | 1,275,355 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $444.80 | $169.55 |
52-Week Low | $121.26 | $104.99 |
Typical Hold Time | 7 Days | 38 Days |
Enterprise Value | $21.18B | — |
Dividend Yield | 0.38% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →